+3
Loading...
Complement C3c is a stable proteolytic fragment derived from complement component 3 (C3), the most abundant protein in the complement system (~1.2–1.5 mg/mL in plasma). C3 exists as a heterodimer comprising α (115 kDa) and β (75 kDa) chains linked by disulfide bonds. Activation via classical, lectin, or alternative pathways cleaves C3 into C3a (anaphylatoxin) and C3b (opsonin), with C3b further processed by Factor I into iC3b and finally C3c (140 kDa) and C3d. Unlike transient C3b, C3c lacks covalent binding capacity, making it a soluble biomarker of complement activation.
C3c quantification in plasma serves as a stable indicator of complement activation in conditions like sepsis and autoimmune diseases. Clinically, C3c assays aid in monitoring lupus and post-transplant rejection. Therapeutic C3 inhibitors (e.g., pegcetacoplan) target C3 cleavage to treat paroxysmal nocturnal hemoglobinuria and geographic atrophy, demonstrating broader potential in C3 glomerulopathy and age-related macular degeneration. Additionally, C3c’s role in immune complex clearance informs drug development for autoimmune and inflammatory disorders.
Common uses include complement and immune system research, IVD assay standards, calibrators and controls.
Not a hazardous substance or mixture.
12 - Non Combustible Liquids
